2004: Bellingbio was established.

2005: Phase I project was completed. 

 The first product "Solanesol" has been successfully put into production.

2006: Obtained the manufacturing license.

 7-ANCA was successfully developed and put into production and sales.

 2007: 7-ANCA maintained its leading position in national sales and production.

2008: Workshop 102 and the warehouse put into production.

 CDCA began production and sales.

 Awarded of the 2008 Cutting-edge Enterprise Award.

2009: Ursodeoxycholic Acid obtained registration approval from the China Food and Drug Administration.

 CDCA had a significant increase in production and sales volume.

 Awarded of “Guangdong Province High-tech Enterprise”.

2010: GMP certificate of Ursodeoxycholic Acid.

 Production and sales of CDCA and UDCA continuously increased.

 Awarded of “Excellent Enterprise of Guangdong Province”.

2011: Workshop 103 and the R&D building has been built.

 Awarded of “Guangdong Province Strategic Emerging Industry Cultivation Enterprise”.

2012: Focused on the bile acid series products and entered into the international market.

2013: Awarded of “Guangdong Province Engineering Technology Research Center”.

 Began the R&D of the innovative traditional Chinese medicine of ZY021.

2014: UDCA was sold to dozens of countries and regions around the world.

2015: The new GMP certificate.

 The production of UDCA broke through 100MT.

2016: Awarded of “Zhongshan City Patent Gold Award” for UDCA production process.

2017: UDCA with enzymatic process put into production.

2018: Awarded of "Guangdong Province Science and Technology Progress Award" for the key technique and industrialization of UDCA.

 Awarded of Provincial Enterprise Technology Center.

 Establishment of Zhongshan Passion Biotechnology Co., Ltd., the wholly-owned subsidiary.

2019: EU CEP certificate of UDCA with chemical process.

 Passed on-site inspection by the US FDA.

2020: Awarded of "Zhongshan City Outstanding Innovation and Entrepreneurship Team".  

 Bellingbio changed to a joint-stock limited company.

2021: Awarded of “Guangdong Province Intellectual Property Demonstration Enterprise”.

2022: EU CEP certificate of Ursodeoxycholic Acid with enzymatic process.

 Passionbio successfully put into production.

2023: The enterprise comprehensively promotes lean management and internal control management.

 Korean MFDS Certificate and Japanese MF Registration of UDCA.

2024: Passed Phase II clinical trials of the innovative traditional Chinese medicine of ZY021.

 Bellingbio is planing the overall industry chain, stepping into a new journey.